RAS

Events

Partner Content

For decades, RAS has existed as an elusive therapeutic target, and drugging this high-value oncogene was deemed impossible.

News

argenx has agreed its second acquisition of the year, buying macrocyclic peptide drug developer Unnatural Products for $550m upfront.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.